Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary endpoint is the disease-free survival rate at 3 years.
Non-small Cell Lung Cancer
DRUG: Furmonertinib
Disease-free survival rate at 3 years, The rate of survival patients without disease recurrence at 3 years, 3 years following the first dose of study drug
Overall survival rate at 3 years, The rate of survival patients at 3 years, 3 years following the first dose of study drug|Median disease-free survival, The median time from the enrollment to the disease recurrence or death depending on the protocol, Approximately 3 years following the first dose of study drugs|Median overall survival, The median time from the enrollment to death of any cause depending on the protocol, Approximately 5 years following the first dose of study drugs|Adverse events, The number of patients with adverse events and the severity according to CTCAE v5.0, Approximately 3 years following the first dose of study drugs
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary endpoint is the disease-free survival rate at 3 years.